IN BRIEF: Indivior Chair Graham Hetherington to retire at year-end
Fri, 04th Oct 2024 11:33
Alliance News
Indivior PLC - Richmond, Virginia-based specialty pharmaceuticals company - On Thursday, the company announced that Chair Graham Hetherington intends to retire from his role and the board at the end of the year for personal reasons. He has served as chair for four years and been a member of the board for five years.
Indivior has started the search to identify a new chair.
Current stock price: 772.00 pence each, up 3.4% on Friday morning in London
12-month change: down 52%
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com |
reverse h+s formation here, if you are into your tea leaves |
Trading update back end of oct |
Feels v much like it |
No idea. Since Feb 2023 it appears to be on a downward trajectory. Has it bottomed? No idea, we've not seen any news or updates from the company. |
Bottom in ? |
Dark atm... |
Last year it was 9th November |
No idea. The 'business update' was in July. |
Anyone know when the next update might be? Might buy back in here at some point.... |
@Hunter... “its always darkest before pitch black” |
very low volume |
“Always darkest before the dawn.”
I have heard Peter Lynch say “its always darkest before pitch black”. Lol
I don't think we are in pitch black category with this stock. |
Some good Medicade re-enrollment + enrollment numbers would in my view help elevate the share price too. |
They operate in around 37 countries which only brings in around 16% of net revenue.... |
Sometimes. What May shift this is an end to any one of the ongoing litigations has been settled or thrown out |
Always darkest before the dawn. |
It's possibly lost investors too. I'm fed up of it, I feel pretty much repelled by it now. |
In around 6 months this has gone from £18 to £7.5.. madness |
Have Blackrock gone limp on us? |
The last notification of a change in shareholding was Bank of America on 13th august where they’d gone from just under 4% held to below 3%.
Does feel like they might still be unloading all of that driving the current price action, and probably triggering a number of stop losses along the way. |
Down another 3 percent, seen 1 green day in 8. |
"AEF0117, which targets disorders linked to cannabis use (addiction and psychosis), has completed a phase 2a trial, which produced positive results in terms of therapeutic efficacy and will enter phase 2b in the United States in 2022. In June 2021, Aelis Farma announced an option licence agreement with Indivior PLC, a pharmaceutical leader in addiction treatment, for the development and worldwide commercialisation of AEF0117 for disorders linked to cannabis use. Under this agreement, Aelis Farma received an initial payment of $30m (for the option to license) and, if the option is exercised after the phase 2b, would receive up to $440m in milestone payments, as well as mid-teens royalties on sales of AEF0117."https://www.euronext.com/en/about/media/euronext-press-releases/aelis-farma-lists-euronext-paris |
The 117 phase 2b results, saved us either 100m or 440m -phewww! |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
